For decades, millions of people with cancer had very few treatment options with only surgery, radiation or chemotherapy available to them, and these treatment options come with difficult side effects and limited therapeutic efficacy. Recently, a fourth approach in immunotherapy has emerged to leverage or manipulate a patient’s own immune system to fight cancer. Ziopharm Oncology is focused on advancing the next generation of immunotherapies to weaponize the existing immune system with Controlled IL-12 or introduce new immune system elements with Sleeping Beauty-modified T cells to this fight against cancer.
In addition to developing the next generation of immuno-oncology medicines that target multiple types of cancers, we also are targeting the cost and complexity of delivering gene and cell therapies. We applaud the significant advances made with newly available CAR-T therapies, but we believe there is now a need to reduce costs and the time associated with centralized manufacturing.
Driven to reinvent
That’s why we are driven to reinvent bioengineering and manufacturing processes to genetically modify T cells. We are developing a non-viral cell therapy platform that has the potential to produce T-cell therapies that are scalable to meet the needs and numbers of patients at a fraction of the cost and time of currently approved therapies.